Post by Biorbyt

If you’re tired of unverified reagents fracturing your in vivo data mid-study, you need to check out this new biosimilar newsletter. We cut straight through the biotech marketing fluff to expose the hidden variables that actually stall preclinical pipelines—like subjective endotoxin thresholds, lot-to-lot glycosylation shifts, and the critical need for mouse-chimeric engineering. It’s a rigorous, no-nonsense resource designed to help you protect your readouts, your grant money, and your sanity.